Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
about
Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysisSyndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationIncreased Oxidative Stress as a Selective Anticancer TherapyNADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells.microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1.Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasion and angiogenesis.Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysProstate cancer cells specifically reorganize epithelial cell-fibroblast communication through proteoglycan and junction pathways.The role of glycans in the development and progression of prostate cancer.Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer.Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Proteoglycans as potential microenvironmental biomarkers for colon cancer.Heparanase 1 involvement in prostate physiopathology.Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype.A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer.
P2860
Q26777707-D37641D4-5A26-4FAA-B7BA-5D98D9F1CD1EQ26784262-1F26E37B-197D-4E47-9945-1E7924F860C6Q26798210-2934AF3C-B19B-4F07-B0F0-DE7AA1D1FD65Q33775852-D325D233-78C9-4512-BF3E-2CE08B1504A6Q35826468-7D982C5C-EC83-4C25-8FC0-8CED8644EC44Q36198174-AD36CC1C-6F16-4523-A380-7399D6CFAD4AQ37686006-2590E5C7-7C69-4234-948A-0AE23976E39DQ38775596-3CC60D15-798E-4679-818C-5A2DB6602786Q38811520-2707FD4E-CD96-4663-9639-68A372654BC5Q38844891-B8FB2F0B-8DF4-42E8-ADA4-67A230E29EC2Q38868904-743DB075-0382-47A1-8B19-769FFAA8CF3FQ38906085-99963400-DD33-4FD0-B91A-ECA74388C0B8Q39138407-488F4DB0-AD66-41F7-9476-2ACE1A81B080Q47134233-ECDDDEBA-BED2-4202-A497-485E1273D3EAQ48026733-97C8D251-7895-4576-AA03-F81B4347DF1DQ49689467-8ADD68DD-9495-49A5-AE8E-01C1530B1D51
P2860
Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Syndecan-1 (CD138) contributes ...... izing tumour-initiating cells.
@en
Syndecan-1
@nl
type
label
Syndecan-1 (CD138) contributes ...... izing tumour-initiating cells.
@en
Syndecan-1
@nl
prefLabel
Syndecan-1 (CD138) contributes ...... izing tumour-initiating cells.
@en
Syndecan-1
@nl
P2093
P2860
P356
P1476
Syndecan-1 (CD138) contributes ...... izing tumour-initiating cells.
@en
P2093
Keiji Shimada
Kiyohide Fujimoto
Noboru Konishi
Nobumichi Tanaka
Satoshi Anai
Tomomi Fujii
P2860
P304
P356
10.1002/PATH.4271
P577
2013-12-01T00:00:00Z